Brean Capital reiterated a Buy rating and $22.00 price target on Keryx Biopharmaceuticals (NASDAQ: KERX) on potential catalysts and improving ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments

Notable 52-Week Highs and Lows 9/3: (TRVN) (NAVB) (BGS) High; (JOY) (KERX) (VRNT) LowSeptember 3, 2015 3:18 PM Unusual 11 Mid-Day Movers 9/3: (KBIO) (PSEM) (MM) Higher; (JOY) (WPCS) (KERX) LowerSeptember 3, 2015 12:59 PM Pre-Open Stock Movers 08/03: (PSEM) (MM) (GERN) (LCI) Higher; (FIVE) (KERX) (JOY) Lower (more...)September 3, 2015 9:29 AM Citi Starts Keryx Biopharmaceuticals (KERX) at SellSeptember 3, 2015 6:58 AM